NOTICE OF SCHEDULE 13G FILING WITH THE UNITED STATES SECURITIES EXCHANGE
Valley Cottage, New York, September 19, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL) hereby notifies that it has just become
aware that on September 18, 2007, a Schedule 13G Filing was made with the
United States Securities Exchange Commission ("US SEC") regarding notification
of a 7.89% beneficial ownership of the Company's Ordinary Shares.
The filing can be found on the US SEC's EDGAR website at http://www.sec.gov/
Ron Bentsur, Chief Executive Officer
Tel: +1-(845)-267-0707 ext. 225